Last reviewed · How we verify
ASP4345
ASP4345 is a small molecule inhibitor of the PI3K delta subunit.
ASP4345 is a small molecule inhibitor of the PI3K delta subunit. Used for Treatment of autoimmune hemolytic anemia.
At a glance
| Generic name | ASP4345 |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, ASP4345 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.
Approved indications
- Treatment of autoimmune hemolytic anemia
Common side effects
- Increased risk of infections
Key clinical trials
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
- A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |